• Vivesto reported positive Paccal Vet pilot study results in dogs with splenic hemangiosarcoma, supporting development toward a registration-enabling trial.
• Treated dogs showed improved survival against historical surgery-only data, with no hypersensitivity reactions observed.
• A feline dose-finding study showed antitumor activity and generally good tolerability; final results were expected in the fourth quarter of 2026.
• Results from both studies were already presented at the Veterinary Cancer Society annual conference and WSAVA World Congress.
• The FDA granted Cantrixil orphan drug designation for acute myeloid leukemia in early November, supporting development toward a Phase 1 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivesto AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.